Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
therapeutics publishing date : 2021 - 06 - 04 save search
Global Coronavirus (COVID-19) Vaccines Markets, 2019-2020 & 2027: Inactivated Virus, Protein Subunit, Non-replicating Viral Vector, Repurposed, RNA, DNA, Genetics
Published: 2021-06-04 (Crawled : 00:20) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
| Email alert
Add to watchlist
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
| Email alert
Add to watchlist
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
BNTX | $86.82 0.75% 0.75% 1.6M
|
Health Technology
| Email alert
Add to watchlist
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
| Email alert
Add to watchlist
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
| Email alert
Add to watchlist
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
| Email alert
Add to watchlist
covid genetic vaccine repurposed
Harpoon Therapeutics Provides Progress Update for TriTAC® Clinical Programs and ProTriTAC™ Platform
Published: 2021-06-04 (Crawled : 22:00) - globenewswire.com
HARP | $23.01 0.07% 6.6M
|
Health Technology
| Email alert
Add to watchlist
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2021-06-04 (Crawled : 21:00) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
| Email alert
Add to watchlist
granted grant
Scientist I/Scientist II, Analytical Development, CMC
Published: 2021-06-04 (Crawled : 20:00) - nurixtx.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
| Email alert
Add to watchlist
Scientist I/Scientist II, Process Chemistry, Chemical Development
Published: 2021-06-04 (Crawled : 20:00) - nurixtx.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
| Email alert
Add to watchlist
First Phase Results of MYLUNG Consortium Provide Historical View of Biomarker Testing Patterns and Identify Data Gaps for Ongoing Prospective Research
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
MCK | $524.83 1.16% -0.05% 650K
|
Distribution Services
|
| O: 0.27%
H: 0.48%
C: 0.29%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.04%
H: 0.82%
C: -0.38%
MRTX | $58.7 -0.17% 0.34% 0
|
Health Technology
|
| O: 3.38%
H: 1.58%
C: -0.87%
ongoing test results research biomarkers
Panbela Presents Clinical Data on Phase 1b Clinical Trial of SBP-101 in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic PDA at 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
PBLA | $0.4895 -6.31% 66K
|
Professional, Scientific, and T...
|
| O: -5.94%
H: 12.18%
C: -4.48%
phase 1 trial phase 1b gemcitabine phase 2b
ADC Therapeutics Presents Updated Clinical Data at 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 20:00) - biospace.com/
ADCT | $4.72 -0.84% 0.0% 320K
|
Health Technology
|
| O: 0.14%
H: 2.02%
C: -1.12%
Sorrento Announces Positive Results From Its License Partner, Kelun, on a Phase I Study of Safety and Pharmacokinetics of A166, a Novel HER2 ADC for Advanced HER2 Positive Breast Cancers
Published: 2021-06-04 (Crawled : 20:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
| Email alert
Add to watchlist
positive results positive results cancer license breast cancer her2+ her2- her2
Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-06-04 (Crawled : 19:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: 1.35%
H: 2.73%
C: 0.32%
research
Scientist, DNA Encoded Chemistry, Library Discovery
Published: 2021-06-04 (Crawled : 18:00) - nurixtx.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.13%
Research Associate/Senior RA, DNA Encoded Scientist, Library Discovery
Published: 2021-06-04 (Crawled : 18:00) - nurixtx.com
NRIX 3 d | $13.6 -5.82% -6.18% 1M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: -2.13%
research
Sorrento and Researchers at Karolinska Institutet Have Signed a Research Collaboration Agreement on iPSC-Derived Dimeric Antigen Receptor-Modified Natural Killer (DAR-NK) Cells With The Vision to Bring “Off-The-Shelf" NK Cell-Based Cancer Treatments Rapidly to Patients
Published: 2021-06-04 (Crawled : 18:00) - globenewswire.com
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
treatment collaboration cancer research
Worldwide CAR-T Cell Therapy Industry - Featuring Aleta BioTherapeutics, Atara Biotherapeutics and BioNTech Among Others
Published: 2021-06-04 (Crawled : 16:00) - prnewswire.com
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: -0.06%
SRNE | $0.024 -8.85% 57K
|
Health Technology
|
| O: 1.73%
H: 2.43%
C: -1.58%
PGEN | $1.33 0.76% 0.75% 1M
|
Health Technology
|
| O: 1.07%
H: 3.01%
C: 0.45%
PSTX | $2.02 1.0% 0.99% 640K
|
Health Technology
|
| O: -1.07%
H: 2.53%
C: 0.84%
MBIO | $0.3451 -6.98% -7.51% 130K
|
Health Technology
|
| O: 2.46%
H: 8.41%
C: 6.91%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.47%
H: 1.17%
C: 0.96%
FATE | $4.795 -4.86% -5.11% 2.7M
|
Health Technology
|
| O: 1.53%
H: 9.81%
C: 6.61%
BLCM | $0.0748 381.28% 6.1K
|
Health Technology
|
| O: 0.0%
H: 2.74%
C: 0.68%
ANIX | $3.12 0.65% 0.64% 33K
|
Health Technology
|
| O: 1.78%
H: 6.25%
C: 3.0%
therapy car-t iot t-cell
Y-mAbs Announces Update on Omburtamab for DIPG
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
|
| O: 1.58%
H: 0.86%
C: -2.78%
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
lung cancer potential cancer trilaciclib
Celldex Presents Preliminary Data from Ongoing CDX-527 Phase 1 Dose Escalation Trial at the 2021 ASCO Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
CLDX | $37.98 -1.43% -1.45% 590K
|
Health Technology
|
| O: 0.86%
H: 1.36%
C: -1.41%
ongoing phase 1 trial phase 3 phase 2
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
GTHX | $4.12 -1.2% -1.21% 730K
|
Health Technology
|
| O: 0.47%
H: 0.42%
C: -1.04%
phase 1 cancer breast cancer phase 3 her2+ her2- her2
Y-mAbs Announces Frontline Data for DANYELZA® (naxitamab-gqgk) in High-Risk Neuroblastoma
Published: 2021-06-04 (Crawled : 13:15) - globenewswire.com
YMAB | $15.15 1.0% 0.99% 470K
|
Health Technology
|
| O: 1.58%
H: 0.86%
C: -2.78%
risk
A Phase 1 Study of RTX-321, an Engineered Red Blood Cell as an Artificial Antigen-Presenting Cell Expressing HLA-A*02 with the HPV-16 E7 Peptide and 4-1BB Ligand with Membrane-Bound IL-12 for the Treatment of HPV 16-Positive Cancers
Published: 2021-06-04 (Crawled : 13:00) - rubiustx.com
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 0.62%
H: 3.05%
C: 1.94%
treatment blood phase 1 positive rtx-321 cancer phase 3
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.